Can Chinese Phase I data from the West accelerate China drug development?

The science of ethnobridging – a way to implement cost-effective, multi-ethnic approaches to global clinical trial research and drug development.


Open PDF

Return to Insights Center

Related Insights

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Video

How early-stage diversity strategies can save time and budget later

Oct 3, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Blog

Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients

Sep 23, 2022

Blog

Best practices and lessons learned in a challenging IBD study

Jul 19, 2023

Video

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Jun 8, 2021

Blog

Population diversity: important considerations in vaccine development

Jun 14, 2023

Article

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Jun 30, 2021

Blog

New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure

Jan 13, 2023

Blog

Xoli Belgrave appointed to lead Parexel’s Clinical Trial Diversity, Equity & Inclusion strategy

Jan 10, 2023

Related Insights

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Video

How early-stage diversity strategies can save time and budget later

Oct 3, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Blog

Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients

Sep 23, 2022

Show more